Airija - anglų - HPRA (Health Products Regulatory Authority)

orion pharma a/s - ethambutol dihydrochloride - tablets - 100 milligram

Airija - anglų - HPRA (Health Products Regulatory Authority)

orion pharma a/s - ethambutol dihydrochloride - tablets - 500 milligram

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine, quantity: 150 mg; zidovudine, quantity: 300 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; propylene glycol; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose - lamivudine and zidovudine combination tablet is indicated for use alone or in combination with other antiretroviral therapies in the treatment of hiv infection.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 75 mg - tablet, film coated - excipient ingredients: lactose monohydrate; betadex; croscarmellose sodium; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol; ferrosoferric oxide - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australija - anglų - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; croscarmellose sodium; betadex; lactose monohydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australija - anglų - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 25 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; betadex; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australija - anglų - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose; lactose monohydrate; croscarmellose sodium; betadex; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australija - anglų - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 100 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; betadex; lactose monohydrate; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australija - anglų - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 10.4 mg (equivalent: perampanel, qty 10 mg) - tablet, film coated - excipient ingredients: purified talc; iron oxide yellow; hypromellose; lactose monohydrate; povidone; indigo carmine aluminium lake; macrogol 8000; titanium dioxide; microcrystalline cellulose; magnesium stearate - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 12.5 mg (equivalent: perampanel, qty 12 mg) - tablet, film coated - excipient ingredients: hypromellose; povidone; microcrystalline cellulose; indigo carmine aluminium lake; purified talc; magnesium stearate; lactose monohydrate; macrogol 8000; titanium dioxide - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.